Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021

1 September 3 , 2021 Santen to Present Latest Data including STN1012700 (DE-127) at APAO 2021 Santen Pharmaceutical Co., Ltd. ( Head Office in Osaka, hereinafter “Santen”) announced today that some publications related to STN1012700 (DE-127), a non-selective muscarinic antagonist, etc. will be presented at the 36th virtual Asia-Pacific Academy of Ophthalmology Congress (APAO 2021 ; https://2021.apaophth.org/) from September 5 to 11, 2021. A Phase 2/3 study of STN1012700 has been conducted to investigate for slowing myopia progression in children in Japan and a Phase 1 study in China is being planned for FY2021. The recent Phase 2 study data of STN1012700 from APPLE study in Asia will be presented at APAO 2021. Presentation topics Session Date and Time Title Pediatric Ophthalmology and Strabismus (Abstract ID: 201344; Presenting author: Chia) Sept 5–11 (on-demand ePoster) Pupil Size Analysis and Efficacy of DE-127 (0.0025%, 0.005%, 0.01%) versus Placebo in Slowing Myopia Progression: The Randomized Phase 2 APPLE Study Pediatric Ophthalmology and Strabismus (Abstract ID: 201350; Presenting author: Chia) Sept 5–11 (on-demand ePoster) Efficacy of DE-127 in Slowing Myopia Progression According to Baseline Spherical Equivalent in the Phase 2 Randomized APPLE Study Glaucoma and glaucoma surgery (Abstract ID: 202170; presenting author: Grover) Sept 5–11 (on-demand ePoster) Outcomes of MicroShunt Implantation vs Trabeculectomy Based on Visual Field Severity: 1- Year Results from a Randomized, Multicenter Study Glaucoma and glaucoma surgery (Abstract ID: 202171; presenting author: Batlle) Sept 5–11 (on-demand ePoster) A 2-year Pooled Analysis of the MicroShunt in Patients with Primary Open-angle Glaucoma 2 In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling STN2000100 (DE-128, MicroShunt) in the Americas, Australia, and New Zealand (press release on May 19, 2021; https://www.santen.com/en/news/20210519-1.pdf). Contact: Investor Relations Group Santen Pharmaceutical Co., Ltd. E-mail: [email protected]

The release as fetched from its publisher. santen.com ↗